Literature DB >> 22175246

Clinical performance assessment of five human papillomavirus DNA tests using liquid-based cytology samples.

Seung Hun Song1, Jin Hwa Hong, San Ha Kwak, Jae Kwan Lee, Mi Kyung Kim.   

Abstract

AIM: To evaluate the performance of five HPV tests (Hybrid Capture 2, Linear Array [LA], DNA chip, type-specific polymerase chain reaction [PCR], and sequencing) in detecting high-risk (HR) HPV DNA and high-grade cervical intraepithelial neoplasia (CIN) and cancer.
MATERIAL AND METHODS: A total of 137 women with abnormal cytologies were prospectively enrolled. The diagnostic accuracy of five HPV DNA tests in detecting high-grade CIN and cancer was assessed, and the concordance among HPV genotyping tests was evaluated. All specimens were obtained from cervical swab samples preserved in residual PreservCyt solution that were originally collected for ThinPrep Pap test.
RESULTS: The sensitivities of all five HPV tests did not differ significantly among the five HPV tests. The overall concordance level was excellent between LA and sequencing (98.2%, Kappa = 0.9) and was substantial between DNA chip and sequencing (96.4%, Kappa = 0.8). The concordance levels for detecting vaccine-type (HPV 16 and 18) of LA in comparison with DNA chip, type-specific PCR, and sequencing were substantial (Kappa = 0.67, 0.64, and 0.65, respectively). The sensitivities for all five HPV tests were >90% for the detection of CIN2 or higher. No statistically significant differences in sensitivity occurred between any of the tests.
CONCLUSION: All five HPV tests showed reliable results in detecting HR HPVs, high-grade CIN, and cancer. Both LA and DNA chip tests may be useful in identifying HR HPV, especially when multiple genotypes are present.
© 2011 The Authors. Journal of Obstetrics and Gynaecology Research © 2011 Japan Society of Obstetrics and Gynecology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22175246     DOI: 10.1111/j.1447-0756.2011.01709.x

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  4 in total

1.  Reproducibility of linear array for human papillomavirus genotyping.

Authors:  Jill Koshiol; S Terence Dunn; Joan L Walker; Rosemary E Zuna; Mark Schiffman; Mark E Sherman; Michael A Gold; Richard A Allen; Roy Zhang; Sophia S Wang; Nicolas Wentzensen
Journal:  J Clin Microbiol       Date:  2012-11-28       Impact factor: 5.948

2.  Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition.

Authors:  Jae Kwan Lee; Jin Hwa Hong; Sokbom Kang; Dae-Yeon Kim; Byoung-Gie Kim; Sung-Hoon Kim; Yong-Man Kim; Jae-Weon Kim; Jae-Hoon Kim; Tae-Jin Kim; Hyun Jung Kim; Hye Sun Kim; Hee-Sug Ryu; Jae Yun Song; Hyeong Sik Ahn; Chong Woo Yoo; Hye-Kyoung Yoon; Keun-Ho Lee; Ahwon Lee; Yonghee Lee; In Ho Lee; Jeong-Won Lee; Taek Sang Lee; Myong Cheol Lim; Suk-Joon Chang; Hyun Hoon Chung; Woong Ju; Hee Jae Joo; Soo-Young Hur; Sung-Ran Hong; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

3.  Comparison of the digene HPV genotyping LQ test and the PANArray HPV genotyping chip for detection of high-risk or probable high-risk human papillomavirus genotypes.

Authors:  Kyung Sun Park; Ji-Youn Kim; Chang-Seok Ki; Nam Yong Lee
Journal:  Ann Lab Med       Date:  2014-06-19       Impact factor: 3.464

4.  Evaluation of the detection of 14 high-risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening.

Authors:  Mei-Lu Bian; Jiao-Ying Cheng; Li Ma; Xiao Cong; Jun Liu; Ying Chen; Xi Chen
Journal:  Exp Ther Med       Date:  2013-09-18       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.